Repotrectinib safety study for ROS1 or NTRK positive cancers
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial is a safety follow-up study for people who are already being treated with repotrectinib in Korea. It looks at how well the drug works and what side effects may occur in patients with ROS1-positive lung cancer or NTRK-positive solid tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 19 years or older if you have non-small cell lung cancer, or 12 years or older if you have another type of solid tumor.
- Your tumor must have a specific gene change called ROS1 or NTRK gene fusion, confirmed by a local test.
- Your cancer must be locally advanced (spread nearby) or metastatic (spread to other parts of the body).
- You must agree to sign a written consent form to participate.
- You cannot have received repotrectinib for a use or at a dose not approved in Korea, and you must not have any medical reason that makes repotrectinib unsafe for you.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study gathers real-world experience with the targeted drug taletrectinib for people with a specific type of advanced lung cancer (ROS1-positive) that has spread to the brain. Participation may help doctors better understand how well the drug works in everyday practice.
This study looks at how well a targeted therapy works for people with advanced non-small cell lung cancer that has a specific genetic change called ROS1. It aims to see if this treatment can help control the cancer and improve outcomes.
This study compares a new targeted therapy pill (taletrectinib) to standard treatments for people with advanced ROS1-positive lung cancer. The goal is to see if taletrectinib works better at shrinking tumors and delaying cancer growth.
This study looks at why the targeted drug entrectinib stops working in some people with ROS1-positive lung cancer. Participants will give blood or tumor samples before and after treatment to help researchers understand resistance.
This trial tests an oral targeted therapy called repotrectinib in people with advanced non-small cell lung cancer (NSCLC) that has a change in the ROS1 gene. It is designed for patients who are either 70 or older, or have a lower performance status (ECOG 2 or higher), meaning they may be more frail or have more symptoms. The goal is to see if repotrectinib can help shrink or control the cancer.
This trial studies repotrectinib, a targeted medicine, in people with advanced solid tumors that have specific gene rearrangements (ALK, ROS1, or NTRK). It may help shrink tumors or control cancer growth based on the patient’s tumor genetic result.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.